| BioCyc:HUMAN_PWY-6307 |
tryptophan degradation via tryptamine |
| BioCyc:HUMAN_PWY66-401 |
superpathway of tryptophan utilization |
| BioCyc:META_PWY-6307 |
L-tryptophan degradation X (mammalian, via tryptamine) |
| BioCyc:META_PWY-5525 |
D-glucuronate degradation I |
| BioCyc:META_PWY3DJ-35471 |
L-ascorbate biosynthesis IV |
| BioCyc:MOUSE_PWY3DJ-35471 |
L-ascorbate biosynthesis VI |
| BioCyc:MOUSE_PWY-5525 |
D-glucuronate degradation I |
| Reactome:R-BTA-1430728 |
Metabolism |
| Reactome:R-BTA-5661270 |
Formation of xylulose-5-phosphate |
| Reactome:R-BTA-156590 |
Glutathione conjugation |
| Reactome:R-HSA-5661270 |
Formation of xylulose-5-phosphate |
| Reactome:R-HSA-211859 |
Biological oxidations |
| Reactome:R-MMU-1430728 |
Metabolism |
| Reactome:R-MMU-5661270 |
Formation of xylulose-5-phosphate |
| Reactome:R-MMU-211859 |
Biological oxidations |
| Reactome:R-RNO-156590 |
Glutathione conjugation |
| Reactome:R-BTA-211859 |
Biological oxidations |
| Reactome:R-HSA-71387 |
Carbohydrate metabolism |
| Reactome:R-HSA-156580 |
Phase II - Conjugation of compounds |
| Reactome:R-MMU-156580 |
Phase II - Conjugation of compounds |
| Reactome:R-RNO-211859 |
Biological oxidations |
| Reactome:R-BTA-71387 |
Carbohydrate metabolism |
| Reactome:R-HSA-156590 |
Glutathione conjugation |
| Reactome:R-MMU-71387 |
Carbohydrate metabolism |
| Reactome:R-MMU-156590 |
Glutathione conjugation |
| Reactome:R-RNO-1430728 |
Metabolism |
| Reactome:R-RNO-5661270 |
Formation of xylulose-5-phosphate |
| Reactome:R-BTA-156580 |
Phase II - Conjugation of compounds |
| Reactome:R-HSA-1430728 |
Metabolism |
| Reactome:R-RNO-71387 |
Carbohydrate metabolism |
| Reactome:R-RNO-156580 |
Phase II - Conjugation of compounds |
| PathBank:SMP0120468 |
Congenital Bile Acid Synthesis Defect Type III |
| PathBank:SMP0120629 |
Aromatase Deficiency |
| PathBank:SMP0120641 |
Corticosterone Methyl Oxidase I Deficiency (CMO I) |
| PathBank:SMP0120649 |
Apparent Mineralocorticoid Excess Syndrome |
| PathBank:SMP0120451 |
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency |
| PathBank:SMP0120463 |
Cerebrotendinous Xanthomatosis (CTX) |
| PathBank:SMP0120467 |
Congenital Bile Acid Synthesis Defect Type II |
| PathBank:SMP0120495 |
Zellweger Syndrome |
| PathBank:SMP0120640 |
21-Hydroxylase Deficiency (CYP21) |
| PathBank:SMP0063672 |
Steroidogenesis |
| PathBank:SMP0120652 |
27-Hydroxylase Deficiency |
| PathBank:SMP0120437 |
17-beta Hydroxysteroid Dehydrogenase III Deficiency |
| PathBank:SMP0120477 |
Familial Hypercholanemia (FHCA) |
| PathBank:SMP0120630 |
17-alpha-Hydroxylase Deficiency (CYP17) |
| PathBank:SMP0120642 |
Corticosterone Methyl Oxidase II Deficiency (CMO II) |
| PathBank:SMP0120650 |
3-beta-Hydroxysteroid Dehydrogenase Deficiency |
| PathBank:SMP0000650 |
Doxorubicin Metabolism Pathway |
| PathBank:SMP0063594 |
Androgen and Estrogen Metabolism |
| PathBank:SMP0063688 |
Androstenedione Metabolism |
| PathBank:SMP0063817 |
Ascorbate Biosynthesis |
| PathBank:SMP0120450 |
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency |
| PathBank:SMP0120470 |
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH |
| PathBank:SMP0120639 |
11-beta-Hydroxylase Deficiency (CYP11B1) |
| PathBank:SMP0063601 |
Bile Acid Biosynthesis |